Updated review of thymosin alpha-1 clinical experience spanning hepatitis B/C, cancer immunotherapy, vaccine adjuvancy, and emerging applications — the most clinically advanced immune peptide drug.
Key findingUpdated review of thymosin alpha-1 clinical experience spanning hepatitis B/C, cancer immunotherapy, vaccine adjuvancy, and emerging applications — th
What the researchers found
Updated review of thymosin alpha-1 clinical experience spanning hepatitis B/C, cancer immunotherapy, vaccine adjuvancy, and emerging applications — the most clinically advanced immune peptide drug.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2010.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Thymosin alpha 1: past clinical experience and future promise.
Annals of the New York Academy of Sciences, 1194, 130-5
Citation
Tuthill, Cynthia; Rios, Israel; McBeath, Randy. (2010). Thymosin alpha 1: past clinical experience and future promise.. Annals of the New York Academy of Sciences, 1194, 130-5. https://doi.org/10.1111/j.1749-6632.2010.05482.x